NIMG-30. ASSESSING TREATMENT RESPONSE OF GLIOBLASTOMA TO AN HDAC INHIBITOR, BELINOSTAT (PXD101)

The current standard of care for glioblastoma (GBM; WHO grade IV glioma) is maximal safe resection followed by radiation therapy (RT) with concurrent and adjuvant chemotherapy. Despite this aggressive treatment, the median survival remains only 15 months. Thus, there is a need for better treatment o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Gurbani, Saumya, Sengupta, Soma, Voloschin, Alfredo, Liang, Zhongxing, Yoon, Younghyoun, Vega, Jose Enrique Velazquez, Holder, Chad A, Olson, Jeffrey J, Shu, Hui-Kuo, Shim, Hyunsuk
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2017
Schlagworte:
Abstracts
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692314/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.605
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge